AMRUBICIN (cas 110267-81-7) and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A phase II trial of the Sarah Cannon Oncology Research Consortium
-
Add time:08/09/2019 Source:sciencedirect.com
PurposeFirst-line treatment for patients with extensive-stage small cell lung cancer (SCLC) includes treatment with platinum-based combination chemotherapy. AMRUBICIN (cas 110267-81-7) is a synthetic anthracycline with single-agent activity in relapsed/refractory SCLC. In an attempt to improve treatment efficacy, we evaluated amrubicin/carboplatin as first-line therapy for extensive-stage SCLC.
We also recommend Trading Suppliers and Manufacturers of AMRUBICIN (cas 110267-81-7). Pls Click Website Link as below: cas 110267-81-7 suppliers
Prev:High expression of topoisomerase-II predicts favorable clinical outcomes in patients with relapsed small cell lung cancers receiving AMRUBICIN (cas 110267-81-7)
Next:Dehydration of 2-(d) - 【Back】【Close 】【Print】【Add to favorite 】